Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin unveils generic...

    Lupin unveils generic version of Viagra in US

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-01T13:32:29+05:30  |  Updated On 1 Oct 2019 1:32 PM IST
    Lupin unveils generic version of Viagra in US

    Lupin’s Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg, is the generic version of Pfizer Inc’s Viagra Tablets, 25 mg, 50 mg, and 100 mg.


    Mumbai: Pharma major Lupin Limited (Lupin) announced the launch of Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.


    Lupin’s Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg, is the generic version of Pfizer Inc’s Viagra Tablets, 25 mg, 50 mg, and 100 mg. Sildenafil Tablets are a phosphodiesterase-5 (PDE5) inhibitor and are indicated for the treatment of erectile dysfunction (ED).


    Also Read: Lupin ropes in Jon Stelzmiller to head US speciality business


    Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg had an annual sales of approximately USD 216 million in the U.S. (IQVIA MAT July 2019).


    Based in Mumbai, Lupin is a player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAI D space and holds a global leadership position in the AntiTB segment.


    Also Read: Lupin Tarapur API facility gets 3 observations from USFDA

    erectile dysfunctionhttp://www.lupin.cominhibitorLupinLupin launchMumbaiPfizerpharmapharma news indiaSildenafilSildenafil tabletsUSUSPViagra

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok